Teijin Ltd - Company Profile
Powered by 
All the sales intelligence you need on Teijin Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Teijin Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Teijin Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Teijin Ltd (Teijin) is a technology-driven holding company that offers solutions in the areas of information and electronics, healthcare, environment and energy and safety and protection. The company manufactures and sells aramid fiber, carbon fiber products, synthetic fiber, films, polyester films, resin products, chemical products, IT products and pharmaceutical products. Teijin offers pharmaceuticals for treating bone and joint diseases, respiratory diseases, cardiovascular and metabolic diseases, and other diseases. It also offers homecare services such as home oxygen therapy devices, sonic accelerated fracture healing systems, and sleep-disordered breathing-related devices, among others. The company operates facilities in Europe, America, Asia and Japan. It sells its products in Asia, the Americas, and Europe. Teijin is headquartered in Tokyo, Japan.
Headquarters
Japan
Address
Kasumigaseki Common Gate West Tower, 3-2-1, Kasumigaseki, Chiyoda-Ku, Tokyo, 100-8585
Website
www.teijin.co.jp
Telephone
81 3 35064529
No of Employees
15,689
Industry
Chemicals
Ticker Symbol & Exchange
3401 (TYO)
Revenue (2025)
$5.6B
-13.2%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-410.4%
(2025 vs 2024)
Market Cap*
$2.1B
Net Profit Margin (2025)
XYZ
-457.5%
(2025 vs 2024)
* As of and is in US$
Teijin Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Materials: | Content | Nesina |
| Aramid Fibers | Synthetic Fibers | Liovel |
| Processed Film | Resin and Plastic Processing Services | Inisync |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In November, the company and BioVaram signed a business alliance agreement to broaden the usage of Teijin Group’s implantable medical devices and regenerative medicine products in India. |
| 2025 | Contracts/Agreements | In October, the company signed an agreement with Cell Therapies Pty Ltd. to enhance CGT infrastructure in the Asia-Pacific, utilizing GMP capabilities in Japan. |
| 2025 | Contracts/Agreements | In October, Teijin Pharma entered into an agreement with Elevara Medicines Limited to develop, manufacture, and commercialize its rheumatoid arthritis drug candidate. |
Competitor Comparison
| Key Parameters | Teijin Ltd | Takeda Pharmaceutical Co Ltd | Sumitomo Chemical Co Ltd | Celanese Corp | Kaneka Corp |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | United States of America | Japan |
| City | Chiyoda-Ku | Chuo-Ku | Chuo-Ku | Irving | Osaka |
| State/Province | Tokyo | Tokyo | Tokyo | Texas | Osaka |
| No. of Employees | 15,689 | 47,029 | 29,279 | 11,434 | 11,512 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Akimoto Uchikawa | Director; Chief Executive Officer; President | Executive Board | 2022 | - |
| Naohiko Moriyama | Chief Financial Officer; Senior Executive Officer; Director; Chief Strategy Officer | Executive Board | 2024 | - |
| Yuji Nakahara | Chief Technology Officer; Director; Corporate Officer | Executive Board | 2025 | - |
| Noboru Yamanishi | Chief Production, Engineering & Procurement Officer; Executive Officer | Senior Management | 2024 | - |
| Fumiaki Sakurai | Chief Human Resources Officer; Chief Sustainability Officer; Executive Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer